A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Last updated: May 6, 2025
Sponsor: Takeda
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bowel Dysfunction

Treatment

Teduglutide

Clinical Study ID

NCT05023382
TAK-633-5001
jRCT2031210284
  • All Genders

Study Summary

The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome.

The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with short bowel syndrome will receive an injection of teduglutide just under the skin (subcutaneous) according to their clinic's standard practice. The study doctors will check for side effects from teduglutide for 36 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All participants in Japan who received teduglutide will be enrolled in this postmarketing surveillance.

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Teduglutide
Phase:
Study Start date:
September 01, 2021
Estimated Completion Date:
February 28, 2026

Connect with a study center

  • Takeda Selected Site

    Tokyo,
    Japan

    Site Not Available

  • Takeda selected site

    Tokyo,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.